Exhibition Invitation | The Inaugural Intelligent Technologies Forum for Drug Discovery and the WeMol User Conference
Release Date:
2025-10-20 15:45
To mark the 10th anniversary of Weixin Computing, we cordially invite all WeMol platform users and pharmaceutical R&D experts to gather in Shanghai for the inaugural Intelligent Technologies in Drug Discovery Forum and WeMol User Conference, to be held on November 8, 2025. With the theme “A New Paradigm for AI-Driven Drug Discovery: From Technology Leadership to Value Creation,” the event will feature presentations by numerous distinguished guests showcasing real-world user case studies, a focused exchange on cutting-edge applications of AI-assisted drug discovery, and an exploration of innovative R&D models that integrate computational and experimental approaches. Zhang Yingbo, Head of the Biotechnology Division at Shanghai Hycells, has also been invited to attend this conference.
Shanghai Hycells Biotechnology Co., Ltd., as a key upstream partner in the AI-driven drug discovery field, leverages a PBMC sample bank comprising over 1,000 Chinese and international donor samples. In collaboration with WeMol’s next-generation AI-based drug design and computational platform, the company employs a dual strategy of AI prediction combined with in vitro experimental validation to efficiently assess the immunogenicity risk of drugs. From subtype-specific PBMCs and pre-screening of donors to its proprietary DC cell induction kit, Hycells not only provides highly precise R&D materials but also continuously expands the scope and depth of immune assessment. With its unique integrated strengths, Hycells is driving the deep integration of AI into drug discovery, delivering tangible value to its partners.
Introduction to Teacher Hycells
Zhang Yingbo
Head of the Technical Department at Hycells
Proficient in the field of macromolecular drugs, with more than 10 years of extensive technical service experience in oncology immunotherapy, ophthalmic diseases, and vaccine development. Previously worked in the Biologics New Drug R&D Services Department at WuXi Biologics Shanghai Co., Ltd. Senior Scientist and Project Leader 。
Currently serves as the Head of the Technical Department at Shanghai Hycells Biotechnology Co., Ltd., with overall responsibility for R&D, technical services, and production management. His professional expertise spans the entire antibody drug development pipeline, from early target identification and in vitro/in vivo efficacy evaluation to preclinical studies ( PCC a full-process R&D system. Proficient in establishing immunogenicity assessment platforms, managing CRO projects, and integrating multiple technology platforms, with the ability to independently initiate projects, conduct feasibility analyses, and lead team execution. In terms of management, has led a 20-person technical team, excelling in cross-departmental collaboration, building standardized R&D and manufacturing systems, and constructing laboratories (P2/GLP-compliant). Capable of effectively formulating R&D strategies, optimizing pipeline prioritization, and driving project implementation. Has repeatedly spearheaded customer technical exchanges, internal training sessions, and project presentations, demonstrating outstanding communication and organizational skills.
Meeting Focus
A New AI-Driven Paradigm for Drug Discovery
Such as the application of generative AI and large models in target identification and molecule generation.
Intelligent Breakthroughs in Antibody Development
Humanized design, affinity maturation, developability, and technical practices in bispecific antibody development
Fusion Innovation of Computational Simulation and Experimental Validation
Industrial-Grade Applications of Free Energy Calculation and Molecular Dynamics Simulation
Next-Generation Drug Discovery Platform Architecture
Automated computing workflows, data governance, and wet-dry closed-loop practices
Meeting Information
Meeting time
Saturday, November 8, 2025 (all day)
Meeting Location
Hyatt Place Shanghai Zhangjiang, 2nd Floor, Huaxia Ballroom A
Meeting Agenda
Register to participate
Conference fees
RMB 800 per person (including a buffet lunch);
Annual subscribers to WeMol can participate free of charge (limited to a maximum of 3 participants per institution).
R&D staff who share this post on WeChat Moments and collect more than 100 likes can apply for a free spot. Spaces are limited—while supplies last, first come, first served.
Please scan the QR code below to register.
Register early to secure your spot.
Business Cooperation
Li Xiaobing
lixb@wecomput.com
13585561092
Related News
(II) Security Assurance Section | Safety First, Defense Prioritized
Compliance‑driven traceability establishes a clear “identity” for the product, but the real test lies in safety. While a multi‑donor pooling strategy ensures batch‑to‑batch consistency, it also inevitably elevates the risk of pathogen introduction. In the face of these associated risks and challenges, Heyousheng has never compromised on its manufacturing standards—relying on more precise design to deliver on its promise of enhanced safety.
This article will examine how He Yousheng proactively integrates the quality management system into the hospital setting, translating compliance requirements into concrete, actionable practices starting at the sample collection stage, thereby establishing a trust‑based chain that can withstand audit scrutiny.
In selecting hPL raw materials, Heyousheng consistently upholds the principle that “safety is determined at the source.” The samples used in production are rigorously collected in accordance with applicable standards and undergo stringent donor screening, effectively mitigating the risk of disease transmission at the very outset. Moreover, from informed consent forms and ethical approvals to clinical‑grade collection under the GCP framework, Heyousheng has established a fully traceable documentation chain, ensuring that every sample is accounted for and verifiable. In contrast to the industry’s longstanding reliance on the conventional model of using expired blood supplies from blood banks, this approach represents a structural, generational upgrade.
Recently, the research team led by Researcher Bian Yingjie at the Guangzhou National Laboratory, in collaboration with partners from Sun Yat-sen University, published a study titled “Iron overload in the tumor microenvironment induces CD8⁺ T cell ferroptosis and dysfunction” in the internationally renowned academic journal Nature Communications.
Hycells Recruitment | Never Stop Exploring, Never Stop Innovating
The company consistently upholds its core values of “people‑centricity, quality first, and innovation as the foundation,” remains driven by technological innovation, and sets new industry benchmarks for domestic innovation, thereby laying a solid foundation for the development and global advancement of China’s innovative pharmaceutical sector.
The HiXpan® NK Serum-Free Culture Kit, Version 3.0, is manufactured in strict compliance with GMP standards, and its production system fully adheres to relevant guidelines and regulations, including the “818 Requirements,” positioning it for pharmaceutical‑grade manufacturing and applications.
Contact Us
Phone: 021-36696819
Mobile phone:13061948224(Ms. Yu)
Email:monika@hys-bio.com
Wuxi Headquarters: 4th Floor, No. 15-1, Xianfeng Middle Road, Anzhen Subdistrict, Xishan District, Wuxi City
Shanghai Branch: Room 503, Building 2, No. 999 Jiangyue Road, Minhang District, Shanghai
Official Website
WeChat Official Account
Message Board